Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer
In conclusion, either utidelone/capecitabine or eribulin chemotherapy may result in a survival benefit with a tolerable adverse effect profile and favorable safety profile in patients with metastatic breast cancer. The first-line use of eribulin resulted in better PFS and ORR than posterior-line use, and the combination of utidelone/capecitabine represents a more efficacious approach in the advanced first-line therapy of breast cancer.
Authors
- Mengya Feng (ORCID: https://orcid.org/0000-0001-7729-026X)
- Xianping Lu (ORCID: https://orcid.org/0000-0003-3933-0931)
- Shengnan Ren
- Guojian Xie
- Dechun Yang
- Dan Mo (ORCID: https://orcid.org/0000-0003-4877-7532)
- Pingping Bi
- Yihua Kang
- Hai Lei
Institutions
- Kunming Medical University (CN)
- The People's Hospital of LinXia (CN)
- Chuxiong Normal University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1186/s12935-024-03608-7
- Citations
- 3
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China
- Yunnan Provincial Science and Technology Department
- Wu Jieping Medical Foundation